Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges

This narrative review focuses on the therapeutic relevance of Vaccinia virus strains in lung cancer models and non-small cell lung cancer patients. The scope covers preclinical and early clinical stages where specific Vaccinia virus strains are shown to modulate immunity under certain conditions. The authors discuss secondary outcomes including direct oncolysis, antitumor immunity activation, inflammatory cell death, recruitment of dendritic cells, tumor-immune interactions, conversion of cold tumors to responsive ones, systemic delivery efficiency, and immunosuppressive feedback.

The authors note that early clinical data in non-small cell lung cancer patients are promising but reveal key obstacles. Specific limitations identified by the authors include inefficient systemic delivery and rapid immunosuppressive feedback within the tumor. These factors may impact the overall efficacy and safety profile of the intervention in a clinical setting.

The review suggests that establishing Vaccinia virus as a robust systemic immunotherapy platform is a relevant practice goal. However, the authors caution that preclinical progress and prospects as a systemic immunotherapy platform must be interpreted with restraint. No specific adverse events, discontinuations, or absolute numbers were reported in this narrative synthesis.